Valeant Pharmaceuticals
May 11, 2017
Valeant’s $50M; Sanofi vows; Top pharmas team up; PhRMA expels
Shadowed by nearly $30B in debt, Valeant's $50M guidance raise looks pretty paltry Faced with a crippling pile of debt, Valeant on Tuesday slightly increased its 2017 earnings guidance, one small positive development as it works to rebound from its noted downfall. The Canadian drugmaker reported first-quarter reven...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
